澳门新葡8455

About Us
Company Profile
Team Introduction
Research Process
Company Culture
Honor

Home - About Us - Company Profile

Company Profile
Xiamen Tongling Biomedical Technology Co., Ltd. was founded in December 2017 by Dr. Guo Jincan, a leading scientist in the United States and the tenth batch of “Double Hundred Plan” in Xiamen. He is the only one in the field of pathological immunohistochemistry. Since its establishment, the company with independent intellectual property core technology has developed into a high-tech enterprise of in vitro diagnostic reagents integrating R&D, production, marketing and sales.
At present, the company has built a 100,000-level international standard GMP production workshop and R&D center with an area of over 1500m2 in the National Torch Program Xiamen (Haicang) Biomedical Characteristic Industrial Base - Xiamen Biomedical Port, with a large-scale industrial chain. Ability. At the same time, 272 products officially put into operation by the company have been sold to major hospitals in China through the filing of the Xiamen Municipal Market Supervision Administration. With its own intellectual property rights, the grape-string polymer multi-antibody standard secondary antibody, a complete range of primary antibody, and the invention of subverting traditional technology, "automated immunohistochemical staining instrument", Psychology is rich in industrial chain. It broke through the technical gap of domestic enterprises in the field of immunohistochemistry and broke the long-term technological monopoly of international enterprises in this field in China.
The development of the company comes from continuous technology-driven and revolutionary innovation. The pathological diagnostic reagents and automated instruments have steadily developed into the eye-catching projects of the future era. Under the heat wave of the special economic zone in Xiamen, Dr. Guo Jincan led the professional technical team to start the HE dyeing technology again. R&D has made a major breakthrough. The application of this technology can not only solve the problem that the traditional HE dyeing technology is easy to cross-contamination and lead to unstable quality, but also can change the workflow of pathological HE production and significantly improve the quality of pathological sections.
In the next 10 years, the company will continue to optimize and improve the existing mature technology fields and automated testing instruments, and follow the pace of the times, from the traditional medical industry, into the modern new media big data operation, dedication A high-quality one-stop service for improving workflow and improving work efficiency for various pathological research and diagnostic institutions around the world.
COPYRIGHT (C) 2018-2020 澳门新葡8455手机版 闽ICP备00000000号-0